Zai Lab Has Dosed The First Patient In The Phase 2 Trial Of ZL-1102 For Chronic Plaque Psoriasis
Portfolio Pulse from Benzinga Newsdesk
Zai Lab has dosed the first patient in the Phase 2 trial of ZL-1102 for chronic plaque psoriasis. This marks the first internally developed drug by Zai Lab to advance to Phase 2, showcasing the company's global capabilities. ZL-1102 is the first topical biologic to show penetration of psoriatic skin resulting in a clinical response based on a proof-of-concept study.
May 22, 2024 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zai Lab has initiated the Phase 2 trial of ZL-1102 for chronic plaque psoriasis, marking a significant milestone as the first internally developed drug to reach this stage. This demonstrates Zai Lab's global capabilities and innovation in the field of topical biologics.
The initiation of the Phase 2 trial for ZL-1102 is a significant milestone for Zai Lab, as it is the first internally developed drug to reach this stage. This progress demonstrates the company's capabilities and innovation, which is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100